Embecta Corp. is a pure-play diabetes care company. Embecta is based in FRANKLIN LAKES, N.J.
| Revenue (Most Recent Fiscal Year) | $1.12B |
| Net Income (Most Recent Fiscal Year) | $78.30M |
| PE Ratio (Current Year Earnings Estimate) | 4.55 |
| PE Ratio (Trailing 12 Months) | 4.56 |
| PEG Ratio (Long Term Growth Estimate) | 0.74 |
| Price to Sales Ratio (Trailing 12 Months) | 0.71 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 3.99 |
| Pre-Tax Margin (Trailing 12 Months) | 9.10% |
| Net Margin (Trailing 12 Months) | 7.58% |
| Return on Equity (Trailing 12 Months) | -23.40% |
| Return on Assets (Trailing 12 Months) | 14.46% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.47 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.78 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 2.35 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-11.45 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.12 |
| Earnings per Share (Most Recent Fiscal Year) | $2.45 |
| Diluted Earnings per Share (Trailing 12 Months) | $1.43 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Common Shares Outstanding | 58.49M |
| Free Float | 58.24M |
| Market Capitalization | $779.02M |
| Average Volume (Last 20 Days) | 0.68M |
| Beta (Past 60 Months) | 1.08 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.42% |
| Percentage Held By Institutions (Latest 13F Reports) | 93.83% |
| Annual Dividend (Based on Last Quarter) | $0.60 |
| Dividend Yield (Based on Last Quarter) | 4.50% |